Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The considerable diversity of HIV worldwide represents a critical challenge for designing an effective HIV vaccine. Now, a scientific team led by Beth Israel Deaconess Medical Center (BIDMC) has shown that bioinformatically optimized HIV vaccine antigens known as "mosaic" antigens might be useful in the design of a global HIV vaccine. This study, which was conducted in monkeys, is published in the journal Cell.
"A global HIV vaccine would offer major biomedical and practical advantages over most other HIV vaccine candidates, which are limited to certain regions of the world," says lead author Dan H. Barouch, MD, PhD, Director of the Center for Virology and Vaccine Research at BIDMC, Director of the Vaccine Program at the Ragon Institute of MGH, MIT and Harvard, and Professor of Medicine at Harvard Medical School. "To our knowledge, this study represents the first evaluation of the protective efficacy of a candidate global HIV antigen strategy in nonhuman primates."
In this new publication, the authors demonstrate for the first time that mosaic HIV vaccine antigens can afford partial protection in rhesus monkeys against challenges with a stringent simian-human immunodeficiency virus. These mosaic vaccine antigens have been developed for optimal immunologic coverage of global HIV diversity.
Barouch and his team studied the immunogenicity of HIV mosaic Env/Gag/Pol antigens administered to monkeys using viral vectors. Env, Gag, and Pol are three major HIV proteins. After immunization, the monkeys were repetitively exposed to multiple simian-human immunodeficiency virus challenges and the investigators evaluated the ability of the vaccines to block infection.
Although most animals immunized with the mosaic HIV vaccine became infected by the end of the study, the researchers observed an 87 to 90 percent reduction in monkeys' probability of becoming infected each time they were exposed to the virus. In contrast, monkeys that received sham vaccines became infected more quickly.
"These findings indicate that these optimized vaccine antigens can afford partial protection in a stringent animal model," says Barouch.
The investigators found that the immunized monkeys mounted antibody responses against diverse strains of HIV noting, "Protection was dependent on several different types of antibody responses, suggesting that the coordinated activity of multiple antibody functions may contribute to protection against difficult-to-neutralize viruses." The monkeys also mounted cellular immune responses to multiple regions of the virus.
The researchers note that most previous HIV vaccine candidates have typically only been testedin monkeys for protection against easy-to-neutralize viruses rather than against a difficult-to-neutralize virus like the one used in this study. Also, each viral challenge in the study was approximately 100-fold more infectious than typical sexual HIV exposures in humans.
"These data suggest a path forward for the development of a global HIV vaccine and give us hope that such a vaccine might indeed be possible," said Barouch. "We are planning to advance this HIV vaccine candidate into clinical trials next year," he adds.
The vaccine regimen tested in the study has two components: The two Ad vaccines are based on the AdVac platform developed by Crucell Holland BV, one of the Janssen Pharmaceutical Companies of Johnson and Johnson, in collaboration with BIDMC. The MVA vaccine was developed by U.S. Military HIV Research Program (MHRP) scientists in collaboration with the National Institutes of Allergy and Infectious Diseases (NIAID) Laboratory of Viral Diseases.
Study coauthors include BIDMC investigators Kathryn E. Stephenson, Erica N. Borducchi, Kaitlin Smith, Kelly Stanley, Anna G. McNally, Jinyan Liu, Peter Abbink, Lori F. Maxfield, and Michael S. Seaman. Other coauthors are from the U.S. Military HIV Research Program (MHRP), the Los Alamos National Laboratory, Crucell Holland BV, and the Laboratory of Viral Diseases at the NIAID. Cell, Volume 155, Issue 3, 531-539, 24 October 2013 10.1016/j.cell.2013.09.061
Support for this work was provided by the U.S. Military Research and Material Command and the U.S. Military HIV Research Program (W81XWH-07-2-0067); the National Institutes of Health (AI052074, AI060354, AI078526, AI084794, AI095985, AI096040, and AI00645); the NIAID Division of Intramural Research; the Ragon Institute of MGH, MIT, and Harvard; and the Bill and Melinda Gates Foundation.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our HIV / AIDS category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Beth Israel Deaconess Medical Center. "Global HIV vaccine that shows promise in monkeys." Medical News Today. MediLexicon, Intl., 28 Oct. 2013. Web.
7 Dec. 2013. <http://www.medicalnewstoday.com/releases/267922>
Beth Israel Deaconess Medical Center. (2013, October 28). "Global HIV vaccine that shows promise in monkeys." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267922.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.